© 1999 American Heart Association, Inc.
Thrombosis |
von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects
The Hoorn Study
From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands.
Correspondence to Dr Coen D.A. Stehouwer, Department of Internal Medicine, University Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands. E-mail cda.stehouwer{at}azvu.nl
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.
Key Words: von Willebrand factor • C-reactive protein • cardiovascular mortality • non–insulin-dependent diabetes mellitus • acute phase reactant
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Accumulating evidence indicates that endothelial dysfunction and chronic low-grade inflammation play a pivotal role in the pathogenesis of atherothrombotic disease.1 2 3
Increased levels of von Willebrand factor (vWf) have been proposed to reflect generalized endothelial dysfunction.4 5 Indeed, subjects with peripheral,6 cerebral,7 and coronary artery atherosclerotic disease8 have increased levels of vWf compared with control subjects. Furthermore, high levels of vWf have been shown to predict cardiovascular mortality in patients recently presenting with cardiovascular disease.7 8 9 10 11 However, 2 population-based studies showed no significant association of high vWf levels with cardiovascular mortality.12 13
C-reactive protein (CRP), an acute-phase reactant, is a marker of inflammation. In healthy subjects, its concentration is generally low, rising 5-fold to >100-fold in acute illness. Slightly increased, but conventionally normal, CRP levels may reflect a chronic low-grade inflammatory state and have been found to be an independent predictor of cardiovascular mortality among subjects at high risk of atherothrombotic events,8 14 15 16 as well as among healthy subjects.17 18 19
Levels of both vWf20 21 and CRP22 are increased in non–insulin-dependent diabetes mellitus (NIDDM) compared with levels in control subjects. NIDDM is associated with a 2- to 4-fold increased cardiovascular mortality,23 but there are few prospective data for vWf and cardiovascular disease in NIDDM21 24 and none for CRP.
We performed a prospective population-based cohort study among nondiabetic and diabetic subjects to investigate the relation between vWf and CRP concentrations on one hand and cardiovascular and all-cause mortality on the other. A further aim of the present study was to investigate whether vWf and CRP affect the risk of mortality through similar pathways. We reasoned that if vWf and CRP confer mutually independent excess risks of mortality, this would argue in favor of the idea that vWf and CRP affect mortality risk through substantially different pathways.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
General Study Design
The Hoorn study is a population-based cohort study of disturbances of glucose tolerance in a white population aged 50 to 75 years conducted from 1989 to 1992 (n=2484 subjects; response rate 71%).25 An extensive investigation was performed in an age-, sex-, and glucose tolerance–stratified random sample (n=631, response rate 89%).25 26 27
From these subjects, we obtained an ankle-brachial blood pressure index (n=631) and a resting ECG (n=625). Subjects were classified as having (1) peripheral arterial disease (PAD) when they had an ankle-brachial pressure index <0.9 in either leg and/or when they had undergone a peripheral arterial bypass or amputation,28 (2) ischemic heart disease (IHD) when they had an ECG with a Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1 and/or had undergone coronary bypass surgery or angioplasty, and (3) cerebrovascular disease when they had evidence of a past transient ischemic attack or stroke according to the World Health Organization (WHO) cardiovascular questionnaire.29
vWf and CRP
Concentrations of vWf and CRP were assessed in deep frozen
(-70°C) heparin plasma samples. No plasma samples were available for
21 subjects. vWf antigen levels were estimated in duplicate by ELISA,
essentially as described,30 with the use of polyclonal
antibodies from Dako (Glostrup, Denmark), and they were expressed as
percentage of vWf detected in pooled citrated plasma of healthy
volunteers. According to the 4th International Standard for vWf in
plasma (NIBSC code 97/586), the pooled citrated plasma contained 1.03
IU/mL of vWf antigen. CRP levels were measured in duplicate with an
enzyme immune assay that used rabbit antibodies against CRP
(Dako) as both the capture and tagging antibody, with a sensitivity of
0.2 mg/L.31 CRP standard serum (Behring
Diagnostics GmbH) was used for calibration. In 11 subjects,
the CRP level was undetectable and therefore set at 0.2 mg/L.
Other Measurements
Data on blood pressure, weight, height, body mass
index, glycated hemoglobin, fasting specific plasma insulin, serum
total cholesterol, HDL cholesterol, and
triglyceride levels were obtained.25 ABO
blood groups were determined by standard agglutination techniques using
commercial test erythrocytes. LDL cholesterol was
calculated by the Friedewald formula,32 except when
the triglyceride level was >4.55 mmol/L (n=23).
Hypertension was defined as diastolic pressure 
95
mm Hg, systolic pressure 160 mm Hg, and/or the use of
antihypertensive drugs.33 Current smoking was defined as
currently smoking cigarettes and/or cigars.
Follow-Up
Data on the vital status of the subjects on April 1, 1997, were
collected from the mortality register of the municipality of Hoorn. Of
49 subjects who moved out of town, information on vital status was
obtained from the new local municipalities. For each subject, we
determined whether or not death had occurred in the first 5 years of
follow-up and, if so, the date at which death occurred. For all
subjects who had died, the cause of death was classified according to
the 9th edition of the International Classification of
Diseases.26 Cardiovascular
mortality was defined as codes 390 to 459; cancer mortality, as codes
140 to 240. Information on cause of death could not be obtained for 6
(10%) of the deceased subjects.
All participants gave informed consent for the present study, which was approved by the local ethics committee.
Statistical Analyses
All analyses were performed with SPSS 7.5 for Windows
95. Survival over 5 years of follow-up was calculated by Kaplan-Meier
curves for different groups, and differences were tested by the log
rank test. Differences between groups in continuous variables that
had a normal distribution were tested by Student t tests; in
continuous variables that had a skewed distribution, by
Mann-Whitney tests; and in percentage of subjects with versus without
the presence of dichotomous variables, by
2 tests. The correlation between vWf and
log-transformed CRP was assessed with the Pearson correlation
coefficient. Predictors of 5-year cardiovascular and
all-cause mortality were determined by Cox proportional hazards
multiple regression analysis (in all cases, because of the
stratification procedure) with adjustment for age, sex, and glucose
tolerance status. Results are described as relative risks (RRs [hazard
ratios]) with 95% CIs.
Potential risk factors measured on a continuous scale were used as such in the regression models, except for HDL cholesterol and body mass index, because the association of these variables with all-cause mortality was nonlinear. Therefore, a low HDL cholesterol level was defined as a level <0.9 mmol/L34 ; obesity, as a body mass index >27 kg/m2 for men and >26 kg/m2 for women.35 Levels of fasting insulin and triglyceride were log-transformed because of a better fit of the regression model. Subjects were grouped according to levels of vWf and CRP. Subjects with levels in the highest tertile were compared with those with levels in the 2 lower tertiles. vWf and CRP were thus entered into the regression models as dichotomized variables, ie, upper tertile versus lower tertiles. (The lowest and middle tertiles were taken together because preliminary analyses showed that the RRs of mortality for these 2 lower tertiles of vWf and CRP were similar, whereas the RR for the upper tertile of vWf and CRP was increased.) To evaluate a possible effect-modifying role of potential risk factors with regard to cardiovascular or all-cause mortality, Cox regression analyses were performed with the risk factor of interest, vWf (or CRP), their product term, age, sex, and glucose tolerance status in the model. A significant RR for the product term was considered effect modification by that risk factor. To assess whether the associations of vWf and CRP with mortality were independent, regression analyses were primarily adjusted for all risk factors that were statistically significant in initial analyses, secondarily adjusted for the presence of cardiovascular morbidity, and finally adjusted for other potential risk factors of interest that showed no significant association in the initial analyses.
To investigate whether vWf and CRP affected risk of mortality through similar pathways, regression analyses were performed that included both vWf and CRP as independent variables. A 2-sided probability value of P<0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Figures 1
and 2 (insets) show the distribution of vWf
and CRP. The ranges of vWf and CRP levels were 0.24 to 3.89 IU/mL and
0.2 to 35.2 mg/L, respectively. Thirty-three (5.4%) of the subjects
had a CRP level >10.0 mg/L. Table 1
shows the baseline characteristics of the study population. Levels of
vWf and CRP in the upper tertile compared with the lower tertiles were
significantly associated with higher age, higher levels of fasting
glucose, glycated hemoglobin, and insulin, and higher body mass index,
systolic blood pressure, and prevalence of NIDDM, hypertension,
and PAD. CRP levels in the upper tertile were, in addition,
significantly associated with higher levels of
triglycerides, higher waist-to-hip ratio, and a higher
prevalence of women, current smoking status, and IHD compared with CRP
levels in the lower tertiles (data not shown).
|
|
|
After 5 years of follow-up, 58 of the 631 subjects had died, of whom 24
(41%) had died of cardiovascular disease. Subjects who
died had higher levels of vWf (mean±SD) and CRP (median interquartile
range) compared with those that survived: 1.76±0.72 versus
1.33±0.68 IU/mL and 3.33 (1.36 to 6.88) versus 1.68 (0.79 to
3.35) mg/L, respectively. Table 1
shows RRs of mortality
associated with potential risk factors.
von Willebrand Factor
In the entire group, vWf levels in the upper tertile were
associated with an 
4-fold increased risk of
cardiovascular mortality (Figure 1) and, after
adjustment for age, sex, and glucose tolerance status, with an
3-fold increased risk (Table 2). After
further adjustment for hypertension, current smoking, low level of HDL
cholesterol, level of triglyceride, IHD, and
PAD, the RR associated with vWf was 3.04 (Table 2). Subgroup
analyses in nondiabetic and diabetic subjects showed that vWf
was associated with a 4-fold and 2-fold increased risk of
cardiovascular death, respectively, after correction
for age, sex, and impaired glucose tolerance (Table 2). Further
adjustment increased the RR associated with vWf to 11.83 among
nondiabetic subjects, whereas the RR among diabetic subjects remained
2.51 (Table 2).
|
The RR of all-cause mortality associated with vWf in the upper tertile
was 2.03, which was not affected by adjustment (Table 2).
To investigate whether the RR of vWf was similar among different risk groups, we performed analyses with interaction terms added (see Methods). Impaired glucose tolerance, NIDDM, current smoking, levels of triglyceride and total cholesterol, body mass index, IHD, and PAD showed no significant interaction (for interaction term, P>0.2). The RRs of cardiovascular mortality associated with vWf in the upper tertile among women, in subjects >65 years of age, and in the presence of hypertension or low levels of HDL cholesterol were 12.3 (P=0.03), 6.5 (P=0.07), 5.0 (P=0.12), and 4.5 (P=0.10) times higher, respectively, than when these factors were absent (data not shown).
The hypothesis has been advanced that the ABO blood group could be the
explanation for the association between vWf level and
cardiovascular mortality, because blood groups are
associated with both cardiovascular disease and levels
of vWf.36 The prevalences of blood groups O, A, B, and AB
were 45%, 39%, 11%, and 6%. After adjustment for age, sex, and
glucose tolerance status, blood group non-O was associated with a
2-fold increased cardiovascular mortality compared with
blood group O (RR 2.08 [95% CI 0.85 to 5.07] among all subjects).
Additional adjustment for risk factors mentioned in Table 2 did
not materially change this result (data not shown). The levels of vWf
were significantly lower in blood group O compared with blood group
non-O (mean±SD 1.16±0.58 and 1.49±0.72 IU/mL, respectively;
P<0.05). The RRs of cardiovascular
mortality associated with vWf level and blood group non-O were not
importantly affected by mutual adjustment (eg, for model 1 in Table 2, RRs 3.02 [1.22 to 7.53] and 1.77 [0.72 to 4.38],
respectively). Further adjustment for risk factors mentioned in Table 2 gave similar results (data not shown). Analyses
performed among blood group O and blood group non-O separately gave
similar results (eg, for model 1 in Table 2, RRs 2.01 [0.42 to
9.51] and 3.28 [1.05 to 10.25] among all subjects,
respectively).
C-Reactive Protein
In the entire group, CRP levels in the upper tertile were
associated with an 3-fold increased risk of
cardiovascular mortality (Figure 2) and, after
adjustment for age, sex, and glucose tolerance status, with an
2-fold increased risk (Table 3). After
further adjustment for hypertension, current smoking, low level of HDL
cholesterol, triglyceride level, IHD, and PAD,
the RR associated with CRP was 1.41 (Table 3). The RRs of
cardiovascular mortality associated with CRP in the
upper tertile were similar among nondiabetic and diabetic subjects
(2-fold). After further adjustment, the RR of CRP decreased to 0.83
among nondiabetic and to 1.34 among diabetic subjects (Table 3).
|
CRP was a significant predictor of all-cause mortality after adjustment
for age, sex, and glucose tolerance status in the entire group (Table 3). After adjustment for other risk factors, the RR decreased
from 1.88 to 1.33 (Table 3).
Impaired glucose tolerance, NIDDM, hypertension, current smoking, low levels of HDL cholesterol, levels of triglyceride and total cholesterol, body mass index, IHD, and PAD showed no significant interaction (for interaction term, P>0.2). The RRs of cardiovascular mortality associated with CRP in the upper tertile among women and subjects older than 65 years were, respectively, 3.6 (P=0.18) and 6.5 (P=0.13) times higher than those among men and subjects aged <65 years (data not shown).
Additional Analyses
The correlation between vWf and log-transformed CRP in the entire
group was 0.10 (P=0.014). The RRs of
cardiovascular mortality associated with vWf and CRP in
their respective upper tertiles were not importantly affected by mutual
adjustment (Table 4). Further adjustment
also did not materially affect the results (Table 4). vWf and
CRP showed no mutual interaction (for interaction term,
P=0.99).
|
Twenty-six (45%) of the subjects died of cancer. After adjustment for age, sex, and glucose tolerance status, both vWf and CRP were not significantly associated with risk of cancer mortality (RRs 1.50 [0.67 to 3.34] and 1.23 [0.54 to 2.82], respectively).
Because the RRs of mortality were similar in the lower tertiles of
either vWf or CRP and increased in the upper tertile only, we further
investigated whether there was a threshold value of vWf and CRP for
predicting mortality by changing the definitions of a "high" vWf
and CRP concentration. When vWf was dichotomized as with 1.22 IU/mL
(median) or 1.74 IU/mL (highest quartile) as cutoffs, the risk
estimates for cardiovascular mortality were slightly
lower (eg, for model 1 in Table 2, RRs 2.36 [0.93 to 5.99] and
2.63 [1.16 to 5.98] compared with 2.80 [1.18 to 6.66],
respectively). When CRP was dichotomized with 2.11 mg/L (used in
Reference 1818 ), 3.20 mg/L (used in Reference 1717 ), or 3.60 mg/L (used in
Reference 1515 ) as cutoffs, the RR of cardiovascular
mortality was lower (eg, for model 1 in Table 3, RRs 1.35 [0.56
to 3.22], 1.93 [0.85 to 4.41], and 1.58 [0.68 to 3.64] compared
with 2.23 [0.95 to 5.21], respectively). Exclusion of subjects with
vWf level <0.50 IU/mL (n=39) or of subjects with CRP level >10.0 mg/L
gave similar results (data not shown). Analyses with a shorter
follow-up duration showed higher RRs of cardiovascular
mortality associated with vWf and CRP levels in their respective upper
tertiles. For example, after adjustment for age, sex, and glucose
tolerance status, the RRs for vWf and CRP in the first 3 years of
follow-up were 4.02 (1.09 to 14.93) and 4.46 (1.14 to 17.41); for 3 to
5 years of follow-up, the values were 1.86 (0.55 to 6.37) and 1.15
(0.32 to 4.10), respectively. The difference between these risk
estimates (the first 3 years compared with 3 to 5 years of follow-up)
was not significant (P=0.40 and P=0.15,
respectively).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This prospective study showed that higher levels of vWf are associated with 5-year cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. This association is independent of conventional risk factors and blood groups. The level of CRP is a predictor of all-cause mortality, which, however, is not independent of other risk factors. Mutual adjustment of vWf and CRP did not markedly affect the RRs of mortality. These results, together with the weak correlation between vWf and CRP at baseline (r=0.10), argue in favor of the idea that vWf and CRP predict mortality through different pathways.
Our finding that vWf is an independent predictor of cardiovascular mortality is in line with results of some7 8 9 10 11 but not all studies.11 12 13 37 38 39 To the best of our knowledge, this is the first study that provides evidence for an independent association of vWf with cardiovascular mortality in the general population. The precise mechanism by which vWf increases cardiovascular risk is unclear. It has been suggested that vWf is a marker of generalized endothelial dysfunction,4 5 which is an important feature of atherothrombotic disease.1 2 3 Alternatively, it has been hypothesized that vWf, as an acute-phase reactant,40 reflects endothelial activation and stimulation (without necessarily implying endothelial dysfunction) and, as such, is a marker of more severe disease in general. Accordingly, the ECAT study (Juhan-Vague et al41 ) showed that among subjects with angina pectoris, the independent RR of cardiovascular mortality associated with vWf disappeared after adjustment for variables related to inflammation, ie, CRP and/or fibrinogen. In other words, the risk predicted by vWf was explained by the risk predicted by CRP and/or fibrinogen. In contrast, we found that mutual adjustment of vWf and CRP did not materially change the risk estimates, suggesting different mechanisms through which vWf and CRP predict mortality. Finally, vWf plays an important role not only in platelet adhesion and aggregation but also in coagulation42 43 and may thus enhance the risk of thrombogenesis. Accordingly, the increase of vWf within 48 hours after a myocardial infarction was a predictor of the rate of restenotic cardiovascular events within 14 days, whereas the increase of CRP, as a marker of acute-phase response, was not.44 Our finding that the RR of mortality associated with vWf is strongest in the first few years of follow-up is compatible with the view that vWf is related more to atherothrombotic than to atherosclerotic disease. In sum, our data are consistent with the concept that a high vWf level, in the general diabetic and nondiabetic population, is a marker of generalized endothelial dysfunction and/or a prothrombotic state but not with the view that a high vWf level reflects an acute-phase response.
Slightly increased levels of CRP have been found to be associated with
increased cardiovascular risk in subjects with angina
pectoris8 14 15 and in healthy
subjects.17 18 19 It has been hypothesized that a chronic
low-grade bacterial infection, which can cause raised CRP levels within
the normal range and is associated with coronary heart
disease,45 46 is the mechanism through which CRP predicts
cardiovascular mortality.18 19 On the
other hand, CRP itself has bioactive properties that may
counterregulate the inflammatory response.46 47 48
Nevertheless, these anti-inflammatory properties have been found only
in studies using concentrations of CRP above the conventional normal
range and may thus be less important for slightly increased levels of
CRP. We found that high CRP levels were associated with a 2-fold
increased risk of cardiovascular mortality. This result
is in partial agreement with previous studies among apparently healthy
subjects.16 17 18 19 First, in contrast to previous
studies,17 18 19 we showed that the association of CRP with
cardiovascular mortality was to a large extent
explained by other risk factors (Table
5). Second, we found that the RR of
mortality for CRP was stronger in the first few years of follow-up,
whereas Ridker et al18 found that this risk was stable in
time, at least up to 8 years of follow-up. Third, we did not find a
linear association of CRP level with mortality, whereas others
did.18 19 Fourth, although we did find evidence for a
stronger association of CRP with mortality risk among women and among
subjects aged >65 years, we could not demonstrate interactions, with
regard to mortality risk, between CRP and current
smoking,16 49 total cholesterol
levels,50 or IHD.16 Fifth, the determinants
of CRP that we found (Table 1) were in line with
some51 but not all previous studies.17 Taken
together, these data suggest that the association between CRP and
cardiovascular mortality differs between populations.
This hypothesis requires further study.
We observed similar associations of vWf and CRP with RR of cardiovascular mortality among nondiabetic and diabetic subjects. NIDDM is associated with a 2- to 4-fold increase of cardiovascular mortality.23 Various hypotheses have been put forward to explain the mechanism through which diabetes accelerates atherothrombosis. Potential glucose-mediated mechanisms include increased oxidative stress, increased concentrations of advanced glycation end products, and activation of the diacylglycerol–protein kinase C pathway,5 52 which can directly or indirectly induce endothelial dysfunction, an acute phase response, and a procoagulant state.5 52 In other words, the associations of vWf and CRP with cardiovascular mortality could be different between diabetic and nondiabetic subjects, because the underlying pathophysiological conditions that cause increased levels of vWf and CRP might be dissimilar. However, from our data, it seems that once levels of vWf and CRP are increased, their associations with cardiovascular mortality are similar among diabetic and nondiabetic subjects.
As has been shown previously, we found higher RRs of mortality associated with vWf12 53 among women than among men. Furthermore, vWf was a stronger predictor in subjects aged >65 years and in the presence of hypertension or a low level of HDL cholesterol. We could neither prove nor disprove the presence of interaction between vWf and these last 3 variables; therefore, more comprehensive studies are necessary to address these issues.
The levels of vWf and CRP were both measured once, which may have led to nondifferential misclassification and, therefore, an underestimation of the RRs associated with mortality. The present study was too limited to assess, with much precision, above what threshold vWf and CRP are associated with mortality. Furthermore, a longer follow-up duration is necessary to establish or exclude definitively the existence of time dependence in the associations of vWf and CRP with mortality risk. Although our data support the concept that levels of vWf and CRP predict cardiovascular mortality through different pathophysiological mechanisms, we did not investigate these possible mechanisms.
We have shown that the level of vWf is a strong independent predictor of cardiovascular and all-cause mortality in the general population, whereas the association of CRP with mortality is confounded by other risk factors. The risk estimates of cardiovascular mortality associated with vWf and CRP were mutually independent, suggesting that vWf and CRP predict mortality through different pathways. This, along with our finding that the risk predicted by vWf seems time dependent (stronger in the first few years of follow-up), gives support to the hypothesis that vWf is more likely to be a marker of risk for atherothrombotic than for atherosclerotic disease. From a therapeutic point of view, this is of clinical relevance, because antithrombotic agents have been shown to reduce the risk of a first myocardial infarction54 and to provide a favorable outcome after a myocardial infarction.44 Therefore, we suggest that the use of antithrombotic agents among subjects with high vWf levels might be particularly effective in reducing the risk of myocardial infarction. Randomized clinical trials are necessary to investigate this hypothesis.
|
Acknowledgments |
|---|
Prof Dr van Hinsbergh and Dr Emeis were supported by a grant from the Praeventiefonds (28-1622-1), and Dr Stehouwer was supported by a Clinical Research Fellowship from the Diabetes Fonds Nederland and the Netherlands Organization for Scientific Research (NWO). We are indebted to J.W.G. Geerdink for her excellent laboratory assistance.
Received February 18, 1999; accepted May 28, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Munro JM, Cotran RS. Biology of disease: the pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249–261.[Medline] [Order article via Infotrieve]
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]
3.
Alexander RW. Inflammation and coronary artery
disease. N Engl J Med. 1994;331:468–469.
4.
Mannucci PM. von Willebrand factor: a marker
of endothelial damage? Arterioscler Thromb Vasc
Biol. 1998;18:1359–1362.
5.
Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh
VWM. Endothelial dysfunction and pathogenesis of
diabetic angiopathy. Cardiovasc Res. 1997;34:55–68.
6. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest. 1997;27:916–921.[Medline] [Order article via Infotrieve]
7. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII:C in acute cerebrovascular disease: relationship to stroke, subtype and mortality. Thromb Haemost. 1997;77:1104–1108.[Medline] [Order article via Infotrieve]
8.
Thompson SG, Kienast J, Pyke SD, Haverkate F, van de
Loo JC. Hemostatic factors and the risk of myocardial infarction or
sudden death in patients with angina pectoris. N Engl J
Med. 1995;332:635–641.
9.
Jansson JH, Nilsson TK, Johnson O. von
Willebrand factor in plasma: a novel risk factor for recurrent
myocardial infarction and death. Br Heart J. 1991;66:351–355.
10. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis. 1997;132:151–156.[Medline] [Order article via Infotrieve]
11.
Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C,
Catalona M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi
L. The PLAT study: hemostatic function in relation to atherothrombotic
ischemic events in vascular disease patients: principal
results. Arterioscler Thromb.. 1992;12:1063–1070.
12.
Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless
LE. Prospective study of hemostatic factors and incidence of
coronary heart disease: the Atherosclerosis
Risk in Communities (ARIC) Study. Circulation. 1997;96:1102–1108.
13.
Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe
GDO. Hemostatic factors as predictors of ischemic heart disease
and stroke in the Edinburgh Artery Study. Arterioscler Thromb
Vasc Biol. 1997;17:3321–3325.
14.
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi
AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and
serum amyloid A protein in severe unstable angina. N Engl
J Med. 1994;331:417–424.
15. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–466.[Medline] [Order article via Infotrieve]
16.
Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW,
Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to
risk of cardiovascular disease in the elderly: results
from the Cardiovascular Health Study and the Rural
Health Promotion Project. Arterioscler Thromb Vasc Biol.. 1997;17:1121–1127.
17.
Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of
C-reactive protein and coronary heart disease in the MRFIT
nested case-control study. Am J Epidemiol. 1996;144:537–547.
18.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens
CH. Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men.
N Engl J Med. 1997;336:973–979.
19.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH.
Prospective study of C-reactive protein and the risk of future
cardiovascular events among apparently healthy women.
Circulation. 1998;98:731–733.
20.
Chen JW, Gall M-A, Deckert M, Jensen JS, Parving H-H.
Increased serum concentration of von Willebrand factor in
non-insulin-dependent diabetic patients with and without diabetic
nephropathy. BMJ.. 1995;311:1405–1406.
21. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540–1545.[Medline] [Order article via Infotrieve]
22. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286–1292.[Medline] [Order article via Infotrieve]
23. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123–131.[Medline] [Order article via Infotrieve]
24. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319–323.[Medline] [Order article via Infotrieve]
25. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn Study. Diabetologia. 1995;38:86–96.[Medline] [Order article via Infotrieve]
26.
Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels
G, Dekker JM, Bouter LM, Stehouwer CDA. Microalbuminuria
and peripheral arterial disease are independent
predictors of cardiovascular and all-cause mortality,
especially among hypertensive subjects: five year follow-up of the
Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617–624.
27. World Health Organization Study Group on Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1985. Technical Report Series, No. 727.
28.
Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP,
Borhani NO, Wolfson SK. Ankle-arm index as a marker of
atherosclerosis in the Cardiovascular
Health Study. Circulation. 1993;88:837–845.
29. Rose GA, Blackburn H. Geneva, Switzerland: World Health Organization Monograph Series; 1968;56:1–188.
30. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:ag). Scand J Clin Lab Invest. 1987;47:143–149.[Medline] [Order article via Infotrieve]
31. Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res. 1996;81:485–490.[Medline] [Order article via Infotrieve]
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.[Abstract]
33. World Health Organization. Arterial hypertension: report of a WHO expert committee. World Health Organ Tech Rep Ser. 1978:7–56.
34. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333–1445.[Medline] [Order article via Infotrieve]
35. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416–422.[Medline] [Order article via Infotrieve]
36. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol. 1994;88:601–607.[Medline] [Order article via Infotrieve]
37. Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84–86.[Medline] [Order article via Infotrieve]
38. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557–1563.[Abstract]
39.
Thögersen AM, Jansson JH, Boman K, Nilsson TJ,
Weinehall L, Huhtasaari F, Hallmans G. High plasminogen
activator inhibitor and tissue
plasminogen activator levels in plasma precede
a first acute myocardial infarction in both men and women.
Circulation. 1998;98:2241–2247.
40. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res. 1989;53:387–394.[Medline] [Order article via Infotrieve]
41.
Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J,
Haverkate F, Thompson SG. Fibrinolytic factors and the risk of
myocardial infarction or sudden death in patients with angina pectoris.
Circulation. 1996;94:2057–2063.
42.
Nichols TC, Bellinger DA, Reddick RL, Koch GG, Sigman
JL, Erickson G, du Laney T, Johnson T, Read MS, Griggs TR. von
Willebrand factor does not influence atherogenesis in arteries
subjected to altered shear stress. Arterioscler Thromb Vasc
Biol. 1998;18:323–330.
43.
Béguin S, Kumar R, Keularts I, Seligsohn U,
Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant
activity requires GPIb receptors and von Willebrand factor.
Blood. 1999;93:564–570.
44.
Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E,
Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C,
Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von
Willebrand factor predicts adverse outcome in unstable
coronary artery disease: beneficial effect of enoxaparin.
Circulation. 1998;98:294–299.
45.
Patel P, Mendall MA, Carrington D, Strachan DP, Leatham
E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ. Association
of Helicobacter pylori and Chlamydia pneumoniae
infections with coronary heart disease and
cardiovascular risk factors. BMJ.. 1995;311:711–714.
46. Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest. 1997;100:522–529.[Medline] [Order article via Infotrieve]
47. Filep J, Foldes-Filep E. Effects of C-reactive protein on human neutrophil granulocytes challenged with n-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor. Life Sci. 1989;44:517–524.[Medline] [Order article via Infotrieve]
48. Kew RR, Hyers TM, Webster RO. Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for the adult respiratory distress syndrome. J Lab Clin Med. 1990;115:339–345.[Medline] [Order article via Infotrieve]
49.
Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M,
Cornell ES, Kuller LH. Lifetime smoking exposure affects the
association of C-reactive protein with cardiovascular
disease risk factors and subclinical disease in healthy elderly
subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167–2176.
50.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein
adds to the predictive value of total and HDL cholesterol
in determining risk of first myocardial infarction.
Circulation.. 1998;97:2007–2011.
51.
Mendall MA, Patel P, Ballam L, Strachan D, Northfield
TC. C-reactive protein and its relation to
cardiovascular risk factors: a population based cross
sectional study. BMJ. 1996;312:1061–1065.
52. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859–866.[Abstract]
53.
Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A,
de Faire U, Mettinger L. Haemostatic function in myocardial infarction.
Br Heart J. 1986;55:58–66.
54. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–135.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  D. I. Buckley, R. Fu, M. Freeman, K. Rogers, and M. Helfand C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med, October 6, 2009; 151(7): 483 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Goldberg Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3171 - 3182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Anvari, M. A. Boroumand, B. Emami, A. Karimi, M. Soleymanzadeh, S. H. Abbasi, and S. Saadat ABO Blood Group and Coronary Artery Diseases in Iranian Patients Awaiting Coronary Artery Bypass Graft Surgery: A Review of 10,641 Cases Lab Med, September 1, 2009; 40(9): 528 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Elliott, J. C. Chambers, W. Zhang, R. Clarke, J. C. Hopewell, J. F. Peden, J. Erdmann, P. Braund, J. C. Engert, D. Bennett, et al. Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease JAMA, July 1, 2009; 302(1): 37 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kooy, J. de Jager, P. Lehert, D. Bets, M. G. Wulffele, A. J. M. Donker, and C. D. A. Stehouwer Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus Arch Intern Med, March 23, 2009; 169(6): 616 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kalyoncu, O. Dizdar, A. Erkan Duman, O. Karadag, A. Tufan, O. Yucel, O. Tayfur, D. Sen, Z. Ulger, A. Kepez, et al. Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation Clinical and Applied Thrombosis/Hemostasis, February 1, 2009; 15(1): 103 - 108. [Abstract] [PDF]
|
|
|
|
 |
|
 A. D. Hingorani, T. Shah, J. P. Casas, S. E. Humphries, and P. J. Talmud C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target? Clin. Chem., February 1, 2009; 55(2): 239 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Frankel, J. B. Meigs, J. M. Massaro, P. W.F. Wilson, C. J. O'Donnell, R. B. D'Agostino, and G. H. Tofler Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study Circulation, December 9, 2008; 118(24): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Chauhan, J. Kisucka, A. Brill, M. T. Walsh, F. Scheiflinger, and D. D. Wagner ADAMTS13: a new link between thrombosis and inflammation J. Exp. Med., September 1, 2008; 205(9): 2065 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Seguin, J. Kassis, L. Busque, A. Bestawros, J. Theodoropoulos, M.-L. Alonso, and E. J. Harvey Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia Rheumatology, August 1, 2008; 47(8): 1151 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R A Pollitt, J S Kaufman, K M Rose, A V Diez-Roux, D Zeng, and G Heiss Cumulative life course and adult socioeconomic status and markers of inflammation in adulthood J Epidemiol Community Health, June 1, 2008; 62(6): 484 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care Clin. Chem., February 1, 2008; 54(2): 234 - 237. [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, N. Khuseyinova, J. Baumert, and C. Meisinger Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998 Clin. Chem., February 1, 2008; 54(2): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Akalin, O. Alatas, and O. Colak Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients Eur. J. Endocrinol., January 1, 2008; 158(1): 47 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Bugnicourt, B. Roussel, B. Tramier, C. Lamy, and O. Godefroy Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 699 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G Casey, M. Joyce, K. Moore, C. Thompson, P. Fitzgerald, and D. J Bouchier-Hayes Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 53 - 61. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Juutilainen, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women Diabetes Care, February 1, 2007; 30(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kahn, B. Zinman, S. M. Haffner, M. C. O'Neill, B. G. Kravitz, D. Yu, M. I. Freed, W. H. Herman, R. R. Holman, N. P. Jones, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes, August 1, 2006; 55(8): 2357 - 2364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. de Jager, J. M. Dekker, A. Kooy, P. J. Kostense, G. Nijpels, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Endothelial Dysfunction and Low-Grade Inflammation Explain Much of the Excess Cardiovascular Mortality in Individuals With Type 2 Diabetes: The Hoorn Study Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1086 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Soinio, J. Marniemi, M. Laakso, S. Lehto, and T. Ronnemaa High-Sensitivity C-Reactive Protein and Coronary Heart Disease Mortality in Patients With Type 2 Diabetes: A 7-year follow-up study Diabetes Care, February 1, 2006; 29(2): 329 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Stam, C. van Guldener, A. Becker, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer Endothelial Dysfunction Contributes to Renal Function-Associated Cardiovascular Mortality in a Population with Mild Renal Insufficiency: The Hoorn Study J. Am. Soc. Nephrol., February 1, 2006; 17(2): 537 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. Best, Y. Zhang, E. T. Lee, J.-L. Yeh, L. Cowan, V. Palmieri, M. Roman, R. B. Devereux, R. R. Fabsitz, R. P. Tracy, et al. C-Reactive Protein as a Predictor of Cardiovascular Risk in a Population With a High Prevalence of Diabetes: The Strong Heart Study Circulation, August 30, 2005; 112(9): 1289 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cushman, A. M. Arnold, B. M. Psaty, T. A. Manolio, L. H. Kuller, G. L. Burke, J. F. Polak, and R. P. Tracy C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study Circulation, July 5, 2005; 112(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. van Hecke, J. M. Dekker, C. D.A. Stehouwer, B. C.P. Polak, J. H. Fuller, A. K. Sjolie, A. Kofinis, R. Rottiers, M. Porta, and N. Chaturvedi Diabetic Retinopathy Is Associated With Mortality and Cardiovascular Disease Incidence: The EURODIAB Prospective Complications Study Diabetes Care, June 1, 2005; 28(6): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Teede, F. S. Dalais, D. Kotsopoulos, B. P. McGrath, E. Malan, T. E. Gan, and R. E. Peverill Dietary Soy Containing Phytoestrogens Does Not Activate the Hemostatic System in Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1936 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ray, D. A. Morrow, C. M. Gibson, S. Murphy, E. M. Antman, E. Braunwald, and for the ENTIRE-TIMI 23 Study Group Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy Eur. Heart J., March 1, 2005; 26(5): 440 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dalla Vestra, M. Mussap, P. Gallina, M. Bruseghin, A. M. Cernigoi, A. Saller, M. Plebani, and P. Fioretto Acute-Phase Markers of Inflammation and Glomerular Structure in Patients with Type 2 Diabetes J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S78 - S82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Fortmann, E. Ford, M. H. Criqui, A. R. Folsom, T. B. Harris, Y. Hong, T. A. Pearson, D. Siscovick, F. Vinicor, and P. F. Wilson CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Population Science Discussion Group Circulation, December 21, 2004; 110(25): e554 - e559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lim, G. Y. H. Lip, and A. D. Blann Plasma von Willebrand Factor and the Development of the Metabolic Syndrome in Patients with Hypertension J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5377 - 5381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bernardo, C. Ball, L. Nolasco, J. F. Moake, and J.-f. Dong Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow Blood, July 1, 2004; 104(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hansen, L. Tarnow, S. Thiel, R. Steffensen, C. D. Stehouwer, C. G. Schalkwijk, H.-H. Parving, and A. Flyvbjerg Association Between Mannose-Binding Lectin and Vascular Complications in Type 1 Diabetes Diabetes, June 1, 2004; 53(6): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. A. Stehouwer Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease Nephrol. Dial. Transplant., April 1, 2004; 19(4): 778 - 781. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Danesh, J. G. Wheeler, G. M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G. D.O. Lowe, M. B. Pepys, and V. Gudnason C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease N. Engl. J. Med., April 1, 2004; 350(14): 1387 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, et al. Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Circulation, March 23, 2004; 109(11): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Schram, N. Chaturvedi, C. Schalkwijk, F. Giorgino, P. Ebeling, J. H. Fuller, and C. D. Stehouwer Vascular Risk Factors and Markers of Endothelial Function as Determinants of Inflammatory Markers in Type 1 Diabetes: The EURODIAB Prospective Complications Study Diabetes Care, July 1, 2003; 26(7): 2165 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Stam, C. van Guldener, C. G. Schalkwijk, P. M. ter Wee, A. J. M. Donker, and C. D. A. Stehouwer Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity Nephrol. Dial. Transplant., May 1, 2003; 18(5): 892 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Imhof, M. Frohlich, H. Loewel, N. Helbecque, M. Woodward, P. Amouyel, G. D.O. Lowe, and W. Koenig Distributions of C-reactive Protein Measured by High-Sensitivity Assays in Apparently Healthy Men and Women from Different Populations in Europe Clin. Chem., April 1, 2003; 49(4): 669 - 672. [Full Text] [PDF]
|
|
|
|
|
|
G. Engstrom, L. Stavenow, B. Hedblad, P. Lind, K.-F. Eriksson, L. Janzon, and F. Lindgarde Inflammation-Sensitive Plasma Proteins, Diabetes, and Mortality and Incidence of Myocardial Infarction and Stroke: A Population-Based Study Diabetes, February 1, 2003; 52(2): 442 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Rabbani, N. A. Seminario, R. R. Sciacca, H. J. Chen, and E.-G. V. Giardina Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1991 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Vlassara, W. Cai, J. Crandall, T. Goldberg, R. Oberstein, V. Dardaine, M. Peppa, and E. J. Rayfield Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy PNAS, November 26, 2002; 99(24): 15596 - 15601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig Is measuring endothelial function a good idea for prediction of coronary heart disease complications? Eur. Heart J., November 2, 2002; 23(22): 1728 - 1730. [Full Text] [PDF]
|
|
|
|
|
|
J. K. Pai, G. C. Curhan, C. C. Cannuscio, N. Rifai, P. M. Ridker, and E. B. Rimm Stability of Novel Plasma Markers Associated with Cardiovascular Disease: Processing within 36 Hours of Specimen Collection Clin. Chem., October 1, 2002; 48(10): 1781 - 1784. [Full Text] [PDF]
|
|
|
|
|
|
B.C. Kuenen, M. Levi, J.C.M. Meijers, A.K. Kakkar, V.W.M. van Hinsbergh, P.J. Kostense, H.M. Pinedo, and K. Hoekman Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1500 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marques-Vidal, E. Mazoyer, V. Bongard, P. Gourdy, J.-B. Ruidavets, L. Drouet, and J. Ferrieres Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers Diabetes Care, August 1, 2002; 25(8): 1371 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kaushal, M. Kohli, M. Zangari, L. Fink, P. Mehta, B. Kuenen, and G. Giaccone Endothelial Dysfunction in Antiangiogenesis-Associated Thrombosis J. Clin. Oncol., July 1, 2002; 20(13): 3042 - 3043. [Full Text] [PDF]
|
|
|
|
 |
|
 C. G.C. Spencer, D. Gurney, A. D. Blann, D. G. Beevers, and G. Y.H. Lip Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Hypertension, July 1, 2002; 40(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig and M. B. Pepys C-Reactive Protein Risk Prediction: Low Specificity, High Sensitivity Ann Intern Med, April 2, 2002; 136(7): 550 - 552. [Full Text] [PDF]
|
|
|
|
|
|
C. D.A. Stehouwer, M.-A. Gall, J. W.R. Twisk, E. Knudsen, J. J. Emeis, and H.-H. Parving Increased Urinary Albumin Excretion, Endothelial Dysfunction, and Chronic Low-Grade Inflammation in Type 2 Diabetes: Progressive, Interrelated, and Independently Associated With Risk of Death Diabetes, April 1, 2002; 51(4): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W.M. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer C-Reactive Protein and Soluble Vascular Cell Adhesion Molecule-1 Are Associated With Elevated Urinary Albumin Excretion but Do Not Explain Its Link With Cardiovascular Risk Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 593 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gade, P. Vedel, H.-H. Parving, and O. Pedersen Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria Nephrol. Dial. Transplant., October 1, 2001; 16(10): 2028 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Borawski, B. Naumnik, K. Pawlak, and M. Mysliwiec Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1442 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Kamphuisen, J. C. J. Eikenboom, and R. M. Bertina Elevated Factor VIII Levels and the Risk of Thrombosis Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 731 - 738. [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W. M. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D. A. Stehouwer Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria Nephrol. Dial. Transplant., March 1, 2001; 16(3): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Volpato, J. M. Guralnik, L. Ferrucci, J. Balfour, P. Chaves, L. P. Fried, and T. B. Harris Cardiovascular Disease, Interleukin-6, and Risk of Mortality in Older Women : The Women's Health and Aging Study Circulation, February 20, 2001; 103(7): 947 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jager, V. W.M. van Hinsbergh, P. J. Kostense, J. J. Emeis, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, and C. D.A. Stehouwer C-Reactive Protein and Soluble Vascular Cell Adhesion Molecule-1 Are Associated With Elevated Urinary Albumin Excretion but Do Not Explain Its Link With Cardiovascular Risk Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 593 - 598. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||